Clinical response and hospital costs associated with the empirical use of vancomycin and linezolid for hospital-acquired pneumonia in a Chinese tertiary care hospital: a retrospective cohort study
Open Access
- 1 October 2014
- journal article
- research article
- Published by Taylor & Francis in ClinicoEconomics and Outcomes Research
- Vol. 6, 451-461
Abstract
Aims: To evaluate clinical outcomes and allocation of hospital costs associated with empirical use of vancomycin or linezolid for hospital-acquired pneumonia (HAP) in the People's Republic of China. Methods: Hospital episodes including HAP treated by vancomycin or linezolid between 2008 and 2012 in a Chinese tertiary care hospital were retrospectively identified from hospital administrative databases. Propensity score methods created best-matched pairs for the antibiotics. The matched pairs were used for adjusted comparisons on clinical response and allocation of hospital costs. Multiple regression analyses adjusting residual imbalance after matching were performed to confirm adjusted comparisons. Results: Sixty matched pairs were created. Adjusted comparisons between vancomycin and linezolid showed similar clinical response rates (clinical cure: 30.0% versus 31.7%, respectively; P=0.847; treatment failure: 55.0% versus 45.0%, respectively; P=0.289) but a significantly lower in-hospital mortality rate for vancomycin (3.3% versus 18.3%, respectively; P=0.013). After further adjusting for the imbalanced variables between matched treatment groups, the risks of treatment failure associated with the two antibiotics were comparable (odds ratio: 1.139; P=0.308) and there was a nonsignificant trend of lower risk of in-hospital mortality associated with vancomycin (odds ratio: 0.186; P=0.055). The total hospital costs associated with vancomycin had a nonsignificant trend of being lower, likely because of its significantly lower acquisition costs (median: RMB 2,880 versus RMB 8,194; P Conclusion: In tertiary care hospitals in the People's Republic of China, empirical treatment of patients with HAP with vancomycin had a comparable treatment failure rate but likely had a lower in-hospital mortality rate when compared with linezolid. Vancomycin also costs significantly less for drug acquisition than linezolid when treating HAP empirically.Keywords
This publication has 20 references indexed in Scilit:
- [Adult hospital acquired pneumonia: a multicenter study on microbiology and clinical characteristics of patients from 9 Chinese cities].2012
- International Nosocomial Infection Control Consortium (INICC) report, data summary of 36 countries, for 2004-2009American Journal of Infection Control, 2012
- Economic Impact of Ventilator-Associated Pneumonia in a Large Matched CohortInfection Control & Hospital Epidemiology, 2012
- International Study of the Prevalence and Outcomes of Infection in Intensive Care UnitsJAMA, 2009
- Epidemiology, etiology, and diagnosis of hospital-acquired pneumonia and ventilator-associated pneumonia in Asian countriesAmerican Journal of Infection Control, 2008
- Modeling the Health Care Costs of Geriatric InpatientsIEEE Transactions on Information Technology in Biomedicine, 2006
- Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated PneumoniaAmerican Journal of Respiratory and Critical Care Medicine, 2005
- [Analysis of nosocomial infection in hospitalized critical and serious patients].1995
- [Nosocomial pneumonia: a report of 372 cases].1992
- [A two-year prospective survey on nosocomial infections].1991